Clinical trials
Oropharyngeal Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 7 |
| Completed | 4 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 4 |
| Shanghai Jiao Tong University School of Medicine | 2 |
| Sun Yat-sen University | 2 |
| Chinese University of Hong Kong | 1 |
| Eye & ENT Hospital of Fudan University | 1 |
| HRYZ Biotech Co. | 1 |
| M.D. Anderson Cancer Center | 1 |
| The Second People's Hospital of Sichuan | 1 |
| Yudong Xiao | 1 |
| Zhujiang Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Oropharyngeal Neoplasms | 15 |
| Mouth Neoplasms | 7 |
| Hypopharyngeal Neoplasms | 2 |
| Anus Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Laryngeal Neoplasms | 1 |
| Nasopharyngeal Neoplasms | 1 |
| Otorhinolaryngologic Diseases | 1 |
| Penile Neoplasms | 1 |
Trials
Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.